Loading…
Insmed Incorporated is projected to rise to $155.15 by 2027, a +34% move from its current price of $115.61. INSM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $112.90 | $115.63 | $118.43 | +0.02% |
| Jul 14 | $111.80 | $115.65 | $119.63 | +0.04% |
| Jul 15 | $110.98 | $115.67 | $120.57 | +0.05% |
| Jul 16 | $110.29 | $115.69 | $121.37 | +0.07% |
| Jul 17 | $109.69 | $115.72 | $122.08 | +0.09% |
| Jul 18 | $109.15 | $115.74 | $122.72 | +0.11% |
| Jul 19 | $108.65 | $115.76 | $123.33 | +0.13% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $108.65 | $115.76 | $123.33 | +0.13% |
| Week 2 | $105.98 | $115.91 | $126.76 | +0.26% |
| Week 3 | $104.00 | $116.05 | $129.51 | +0.38% |
| Week 4 | $102.38 | $116.20 | $131.89 | +0.51% |
| Week 5 | $100.99 | $116.35 | $134.05 | +0.64% |
| Week 6 | $99.76 | $116.50 | $136.05 | +0.77% |
| Week 7 | $98.65 | $116.65 | $137.92 | +0.90% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, and is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa.
In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. It also develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis.
The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Insmed Incorporated, a healthcare company, operates with a focus on therapies for serious and rare diseases. The stock is currently priced at $111.60 per share, with a market capitalization of $24.19B and a market rank of 514. The current price sits in the context of a long horizon forecast that envisions a rising average price and expanding upside through the coming years.
The forecast suggests a neutral start in 2026, followed by a bullish trajectory in subsequent years.
A major floor 28.9% below — a decisive break under it would weaken the trend.
The nearest floor, 20.5% below — buyers have tended to step in here.
Price is pressing into resistance (2.3% away) — a breakout level to watch.
A major ceiling 42.6% above — clearing it would confirm fresh momentum.
Key INSM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of INSM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $114.96 | Buy | $114.70 | Buy |
| MA 10 | $110.81 | Buy | $111.57 | Buy |
| MA 20 | $104.93 | Buy | $108.44 | Buy |
| MA 50 | $109.11 | Buy | $112.92 | Buy |
| MA 100 | $128.79 | Sell | $124.54 | Sell |
| MA 200 | $151.01 | Sell | $131.00 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.71 | Neutral |
| Stoch RSI (14) | 78.57 | Neutral |
| CCI (20) | 117.57 | Buy |
| Williams %R (14) | -13.49 | Info |
| MACD (12,26,9) | 2.32 | Buy |
| ROC (12) | 13.18 | Buy |
| Bollinger %B (20,2) | 0.87 | Neutral |
| Stochastic %K (14) | 86.51 | Sell |
| TRIX (15) | -0.01 | Sell |
| Awesome (5,34) | 10.76 | Buy |
| Ultimate (7,14,28) | 79.06 | Sell |
| Momentum (10) | 11.14 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 118.63 | Sell |
| ADX (14) | 20.48 | Buy |
| ATR (14) | 2.38 | Info |
Technically, the sentiment is BULLISH with RSI14 at 60. The 50-day simple moving average sits at $111.50 and the 200-day simple moving average at $151.76. Support is identified at $91.88 and resistance at $111.60. The 30-day price range runs from a low of $93.84 to a high of $132.72, and annualized volatility stands at 50%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $91.88 | $115.61 | $150.20 | 0% | Neutral | |
| $124.92 | $155.15 | $202.95 | +34% | Bullish | |
| $140.46 | $178.70 | $241.60 | +55% | Bullish | |
| $143.45 | $186.17 | $258.31 | +61% | Bullish | |
| $154.85 | $204.54 | $290.04 | +77% | Bullish | |
| $160.79 | $215.78 | $311.90 | +87% | Bullish | |
| $177.66 | $241.99 | $355.83 | +109% | Bullish | |
| $213.12 | $294.33 | $439.59 | +155% | Bullish | |
| $232.13 | $324.83 | $492.16 | +181% | Bullish | |
| $248.51 | $352.13 | $540.70 | +205% | Bullish | |
| $362.58 | $543.65 | $882.96 | +370% | Bullish | |
| $558.39 | $921.48 | $1,625.02 | +697% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $91.88 | $115.61 | $140.56 | +0.00% |
| August 2026 | $100.19 | $117.88 | $142.16 | +1.97% |
| September 2026 | $99.30 | $117.55 | $143.14 | -0.28% |
| October 2026 | $101.63 | $120.93 | $148.48 | +2.88% |
| November 2026 | $102.30 | $122.28 | $151.17 | +1.11% |
| December 2026 | $100.59 | $120.72 | $150.20 | -1.27% |
Click any year to see its month-by-month INSM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Insmed Incorporated's 2026 outlook centres on $115.61, within a $91.88 to $150.20 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, INSM could reach as high as $202.95, with a base case around $155.15 and support toward $124.92 — roughly +34% from $115.61. Buyers look set to stay in control over this stretch.
Expect INSM to range from $140.46 to $241.60 through 2028. The $178.70 average target implies a +55% move from current prices. That is up +15% on the projected 2027 average. Momentum favours further upside here.
The INSM price prediction for 2029 points to an average of $186.17 (low $143.45, high $258.31) — a potential gain of +61% on today's $115.61. Buyers look set to stay in control over this stretch.
In 2030, INSM is projected to trade between $154.85 and $290.04, averaging $204.54 — a potential gain of +77% from today's $115.61. That is up +10% on the projected 2029 average. Momentum favours further upside here.
Insmed Incorporated's 2031 outlook centres on $215.78, within a $160.79 to $311.90 range. That is up +5% on the projected 2030 average. That marks a +87% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, INSM could reach as high as $355.83, with a base case around $241.99 and support toward $177.66 — roughly +109% from $115.61. Momentum favours further upside here.
Expect INSM to range from $213.12 to $439.59 through 2033. The $294.33 average target implies a +155% move from current prices. That is up +22% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The INSM price prediction for 2034 points to an average of $324.83 (low $232.13, high $492.16) — a potential gain of +181% on today's $115.61. Momentum favours further upside here.
In 2035, INSM is projected to trade between $248.51 and $540.70, averaging $352.13 — a potential gain of +205% from today's $115.61. That is up +8% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Insmed Incorporated's 2040 outlook centres on $543.65, within a $362.58 to $882.96 range. That is up +54% on the projected 2035 average. That marks a +370% change versus current levels. Momentum favours further upside here.
By 2050, INSM could reach as high as $1,625.02, with a base case around $921.48 and support toward $558.39 — roughly +697% from $115.61. Buyers look set to stay in control over this stretch.
Investing $1,000 in INSM today (≈ 8.649771 INSM) could be worth
$7,970.59
+$6,970.59 (+697%) by 2050 · US Dollar
Based on the average projected INSM price of $921.48 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in INSMwould be worth at today's price.
$1,000 invested in INSM on Jul 10, 2025 (≈ 10.345541 INSM) would be worth
$1,196.05
+$196.05 (+19.6%) today · 1.20× · US Dollar
Based on a INSM entry price of $96.66 vs. today's $115.61.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $111.6 | $1,035.93 | +3.6% |
| 1 month ago | $91.88 | $1,258.27 | +25.8% |
| 3 months ago | $154.81 | $746.79 | -25.3% |
| 6 months ago | $167.72 | $689.3 | -31.1% |
| 1 year ago | $96.66 | $1,196.05 | +19.6% |
| All time (5.0y) ago | $28.51 | $4,055.07 | +305.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our INSM forecast.
Our base-case forecast reaches $230.00 around 2032.
Implied market cap at $230.00: $49.85B
The multi-year forecast shows a clear upward trajectory, with the average price progressing through subsequent years and a rising series of max values. In 2027 the avg is $149.09 with ROI 33.6 and bullish sentiment, followed by 2028 avg $168.46 (ROI 51) and 2029 avg $171.02 (ROI 53.2). The 2030 avg is $187.47 (ROI 68) and 2031 avg $192.83 (ROI 72.8), with continued strength into 2032 at $212.56 (ROI 90.5) and 2033 at $260.41 (ROI 133.3).
By 2034 the forecast shows avg $283.47 (ROI 154) and 2035 avg $306.72 (ROI 174.8). The trajectory accelerates further in the long horizon, with 2040 avg $456.93 (ROI 309.4) and 2050 avg $751.88 (ROI 573.7), both signaling bullish momentum. These are estimates and carry inherent uncertainty and are not guarantees.
Tap a question to reveal the answer.
The forecast shows an average of $187.47 per share in 2030, with a min of $139.78 and a max of $270.74; ROI 68; sentiment BULLISH.
Forecasts show bullish sentiment continuing from 2027 onward, with rising averages and ROI: 2027 avg $149.09 ROI 33.6%; 2028 avg $168.46 ROI 51; 2029 avg $171.02 ROI 53.2%; 2030 avg $187.47 ROI 68%. These are estimates, not guarantees.
Yes. The forecast includes years with max values above $300: 2032 max $319.19; 2033 max $397.64; 2034 max $439.57; 2035 max $482.48; 2040 max $763.22; 2040 min $295.52.
Current price is $111.60. The 30-day range is from $93.84 to $132.72.
For 2040 the avg is $456.93 with ROI 309.4. For 2050 the avg is $751.88 with ROI 573.7. Both years are labeled bullish.
Insmed Incorporated Community Discussion
0Share your Insmed Incorporated price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.